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Клинический случай поздней диагностики системной склеродермии и легочной 
артериальной гипертензии
Л. И. Васильева, Е. Д. Егудина, О. С. Калашникова
Легочная гипертензия является частым и серьезным осложнением системной склеродермии. Прогноз у пациентов с легоч-
ной артериальной гипертензией, ассоциированной со склеродермией, хуже в сравнении с пациентами с идиопатической 
легочной артериальной гипертензией. 
Представили клинический случай поздней диагностики системной склеродермии и ассоциированной с ней легочной 
артериальной гипертензии. У пациентки в возрасте 61 год с 20-летним анамнезом синдрома Рейно была впервые диагно-
стирована лимитированная форма системной склеродермии на стадии выраженных проявлений легочной гипертензии 
со средним давлением в легочной артерии 48 мм рт. ст., тяжелой правожелудочковой сердечной недостаточностью 
и III ФК NYHA. Это подчеркивает необходимость осведомленности и своевременной диагностики лимитированной 
формы склеродермии и требует повышенного внимания в раннем выявлении легочной гипертензии у таких пациентов.
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Clinical case of delayed systemic sclerosis and pulmonary arterial 
hypertension diagnostics
L. I. Vasylieva, Ye. D. Yehudina, O. S. Kalashnykova*
State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro
Pulmonary hypertension is a frequent and severe complication of systemic sclerosis (SSc). SSc-PAH patients have a worse 
prognosis than patients with idiopathic PAH. 
We report a case of a patient with delayed SSc and PAH diagnostics. Limited SSc was established in a 61-year-woman with 
20 years of Raynaud’s syndrome anamnesis. But diagnosis of SSc-PAH was determined in severe and late symptomatic 
stage with signs of right heart congestion, NYHA III FC and mPAP 48 mmHg. This emphasizes the need for clinicians to be 
aware of limited SSc and have a high index of PH suspicion in such patients.
Клінічний випадок пізньої діагностики системної склеродермії та легеневої 
артеріальної гіпертензії
Л. І. Васильєва, Є. Д. Єгудіна, О. С. Калашникова
Легенева гіпертензія є частим та загрозливим ускладненням системної склеродермії. Прогноз у пацієнтів із легеневою 
артеріальною гіпертензією, що асоційована зі склеродермією, гірший порівняно з пацієнтами з ідіопатичною артеріальною 
гіпертензією. 
Наведений клінічний випадок пізньої діагностики системної склеродермії та асоційованої з нею легеневої артеріальної гіпер-
тензії. У пацієнтки віком 61 рік з 20-річним анамнезом синдрома Рейно вперше діагностована лімітована форма системної 
склеродермії на стадії виражених проявів легеневої гіпертензії із середнім тиском у легеневій артерії 48 мм рт. ст., тяжкої 
правошлуночкової серцевої недостатності та III ФК NYHA. Це показує необхідність обізнаності та своєчасної діагностики 
лімітованої форми склеродермії та потребує посиленої уваги в ранньому виявленні легеневої гіпертензії в таких хворих.
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Systemic sclerosis (SSc) is a multiorgan autoimmune 
connective tissue disease characterized by vasculopathy 
and fibrosis. The prevalence of SSc ranges from 7 million 
to 489 million [1].
Cardiorespiratory complications, such as pulmonary 
hypertension (PH) and intersticial lung disease are the main 
causes of mortality in SSc patients [2]. Different types of PH 
may occur in SSc patients: pulmonary arterial hypertension 
associated with SSc (SSc-PAH), pulmonary veno-occlusive 
disease (PVOD), pulmonary hypertension associated with 
intersticial lung disease (PH-ILD), pulmonary hypertension 
associated with left heart disease (PH-LHD). Among them 
SSc-PAH is the most common studied variant with preva-
lence of 8–15 % [3,4] and significantly lower survival rate 
in comparison with idiopathic PAH [5,6]. Without treatment 
the average life expectancy after symptoms manifestation 
has been 2–3 years [7]. Patients with teleangiectasia, 
anti-centromere antibodies, older age and longer disease 
duration are at the higher risk for developing PAH [8–10]. In 
Ukraine there is lack of epidemiological studies on PAH in 
SSc. According to the registry of SSc patients established 
in the Rheumatology Department of Mechnikov Dnipro-
petrovsk Regional Clinic the pulmonary artery pressure 
assessed by transthoracal echocardiography (TTE) was 
23 mmHg in 190 patients with SSc, among them 25.3 % 
had pulmonary fibrosis [11].
Significant efforts have been made to improve the di-
agnostics and classification of PH. According to ESC/ERS 
guidelines 2015 PH is defined as mPAP of 25 mmHg or 
greater obtained by cardiac catheterisation at rest [12]. In 
March 2018, on the 6 World Symposium of PAH in NICE 
a new PH haemodynamic definition was proposed. Thus, 
mPAP >20 mmHG should be considered as upper normal 
value and pre-capillary PH could be defined as mPAP 
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>20 mmHg, pulmonary artery wedge pressure (PAWP) 
<15 mmHg and pulmonary vascular resistance (PVR) 
>3 WU. This definition allows to identify pulmonary vascular 
disease at an earlier stage. The impact of the new definition 
on the number of pre-capillary PH patients identified would 
be low with preliminary data suggesting an increase of less 
than 10 % [13]. In the study of Coghlan et al., 71 patients 
with SSc were clinically assessed at baseline and after 3 
years, including right heart catheterisation (RHC). Among 
them 3 % developed PH and 7 % developed SSc-PAH. 
PVR, tricuspid regurgitation velocity, diffusion capacity 
and the size of the inferior vena cava at baseline were 
independent predictors for the development of PH during 
follow-up [14].
Another study of J. V. Cristopher et al. demonstrates, 
that 16 SSc patients with borderline mPAP from 21 to 
24 mmHg have developed manifest PAH at the time of 
follow-up RHC (median follow up 45 months). At baseline 
catheterization these 16 patients with borderline PH had 
mPVR of 2.9 WU and it increased to 4.9 WU at follow up. 
Patients with borderline mPAP were more likely to develop 
PH than patients with mPAP ≤20 mm Hg [15].
SSc-PAH belongs to Group 1 disease of the PH clas-
sification, at the same time the number of SSc patients 
with mPAP > 20 mmHg and PAWP > 15 mmHg at rest is in 
the range of 20–45 % [16,17]. After significant parenchymal 
lung disease exclusion, they will be classified as PH due 
to SSc-PH-LHD, or Group 2 of the PH classification [12]. 
The underlying causes of LHD can include the presence or 
absence of valvular heart disease, heart failure with reduced 
ejection fraction or heart failure with preserved ejection 
fraction. Elevation in pulmonary vascular pressures can 
be related to several mechanisms: passive transmission of 
pressures from the left atrium, changes in vascular compli-
ance due to elevated left atrial pressure [18] and changes 
in the pulmonary vascular tone or vascular remodeling.
Another challenge to the PH specialist may be di-
agnostics and treatment of PVOD in suspected SSc-PH 
patients. This condition remains poorly understood and 
accounts for 5–10 % of cases initially misdiagnosed as 
IPAH. Haemodynamic presentation of PVOD is similar to 
IPAH, particularly with respect to wedge pressure, which is 
invariably normal in both disease conditions [19,20], that 
was reflected in the ESC/ERS guideline PH 2009 [12]. 
In updated clinical classification (Nice 2018) PVOD was 
determined as PAH with overt sings of venous / capillaries 
(PVOD/PCH) involvement [13]. Recent genetic studies 
have shown that PVOD occurs sporadically or is inherited 
in families due to recessive mutations of the eukaryotic 
translation initiation factor 2 alpha kinase 4 (EIF2AK4) gene 
which encodes the GCN2 protein [21]. Clinicians should 
be aware in cases, when patient experiences worsening 
after initiation of the specific PAH treatment or becomes 
refractory to this therapy.
Major finding that has important implications for both 
the initial clinical classification of SSc-PH patients and 
their long-term management is change in hemodynamic 
classification over time. In the PHAROS cohort [22], 30 % 
of patients changed their PAWP on follow-up RHC to 
the degree where they cross over the PAWP classification 
threshold of 15mmHg, including almost one-quarter of pa-
tients who had an initial PAWP ≤15 mmHg. This occurred 
independently of whether the patient was placed on a PH 
medication. In the REVEAL registry, 16 % of PAH patients 
with mixed etiology changed their PAWP enough on fol-
low-up to have what is termed a “PAWP class change”, at 
the same time 65 % of patients with a PAWP >15 mmHg 
had a PAWP <15 mmHg on repeat RHC [23]. There are 
several explanations why PAWP may truly change in 
SSc-PH patients. First, patients who develop an elevated 
PAWP over time may simply have developed heart failure 
with preserved ejection fraction in addition to their under-
lying PH, since heart failure is a disease associated with 
aging and diastolic dysfunction which is common in SSc 
[24]. But in the PHAROS study no increased baseline 
diastolic dysfunction was found in patients with an initial 
PAWP <15 mmHg who had an elevated PAWP on their 
follow-up RHC, there were no differences in TTE mea-
surements of diastolic dysfunction or left atrial size when 
performed at the time of the second RHC, making progres-
sive development of heart failure with preserved ejection 
fraction less likely [23]. Second, either improvements or 
decrements over time in right ventricular (RV) function can 
alter left heart filling pressures by RV-LV interdependence 
[25]. And the last one, therapies such as diuretics and PH 
medications may have altered PAWP.
SSc being a well-known risk factor for developing PAH, 
but there are still delays in diagnosing PAH and conse-
quently more than 80 % of patients present with the World 
Health Organization (WHO) functional class III or IV at this 
point [26]. Coghlan et al. reported the first evidence-based 
algorithm (DETECT) for the screening of PAH in SSc [9]. 
The DETECT algorithm is a tool to identify patients with PAH 
in the asymptomatic stages, through the study of clinical 
variables, pulmonary function tests, immunological, bio-
logical, electrocardiographic and finally, echocardiographic 
parameters. The application of the DETECT algorithm was 
conducted in two steps through the website PAH risk calcu-
lator (http://detect-pah.com) [27], the first step for referring 
the patient for echocardiography and the second for carrying 
out RHC [26]. The ESC/ESR 2015 PH guidelines introduce 
the DETECT algorithm as a valid method to be performed 
for annual screening of PAH in patients with SSc [12].
It is a very common situation for SSc patients, when 
several mechanisms can work together and lead to PH. 
Careful phenotyping of PH in SSc is very important because 
it has an impact on treatment choice, therefore different 
treatments and strategies are indicated for the different 
subgroups of patients.
Despite the attention that PH has drawn in recent years, 
significant gaps remain in the management of challenging 
cases of PH in Ukraine.
In September 2016 a 63-year-old female presented 
to the centre with mixed dyspnea on a moderate exertion 
progressively increased over the last year; fatigue; episodes 
of burning or tightness in the chest and pain lasting more 
than a few minutes, getting worse with activity; chronic ankle 
edema; two pillow orthopnea for 2 months; pain in fingers 
and toes, their paleness, sensations of cold and numbness; 
back pain; dizziness while walking.
In 2015, the patient was hospitalized due to angioparal-
itic stage of Raynaud’s syndrome to the Rheumatology 
Department of the City Hospital. She had peripheric artery 
disease with involvement of forearm and tibial arteries 
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without hemodynamic abnormality. She noted a history of 
Raynaud’s syndrome and sclerodactyly for more than 20 
years, but she was not examined for scleroderma. Her medi-
cal history also included anamnesis of arterial hypertension 
for 35 years and ischemic stroke (March 2015). The patient 
was in menopause for 10 years, had one pregnancy with 1 
normal birth in anamnesis.
Physical examination of the patient identified sclero-
dactyly, cyanosis, jugular vein pulsation. Thyroid gland 
was normal without masses. There was no adenopathy. 
Chest was hyposthenic and symmetric, nontender without 
masses or discharges. BMI was 26.7. RR was 22 per mi-
nu te. Lung fields were clear to auscultation. BP was 145/95 
mmHg sitting, HR was 92 per minute. Cardiac auscultation 
revealed systolic murmur on the left parasternal border and 
enhanced P2. Abdomen was symmetrical, soft, flat, bowel 
sounds were present, no bruits, nontender to palpation. 
Flunk dullness was noted on percussion. Liver edge was 
+2 cm, spleen, kidney did not palpate. Extremities examina-
tion revealed sclerodactyly, signs of chronic venous stasis 
changes in both legs, 1+ edema until the knees.
Bendopnea test [28,29]: BP was 130/85 mmHg and BR 
was 4 within 15 seconds in sitting position. While bending 
30 seconds dyspnea occurred on the 10 second. After 
the patient returned in sitting position BP was 138/92 mmHg, 
BR was 7 within 15 seconds.
The 6-MWT distance was 192 meters with desaturation 
from 95 % to 91 % and pulse increased from 96 to 118 
beats per minute. Borg dyspnea score was assessed as 4.
Chest radiography revealed increased cardiothoracic 
ratio, clear lung fields with prominent central pulmonary 
arteries.
On ECG, there was left axis deviation, rhythm was 
sinus with HR 87 per minute and amplitude signs of right 
atrium enlargement.
The result of spirometry (FEV1 84 %, FEV1/ FVC 126) 
did not reveal any abnormalities.
Clinical blood analysis: HGB 158 g/L, RBC 4.8 1012 /L, 
WBC 7.1 109 /L; Platelets 202 g/L.
Biochemical analysis: total bilirubin 8 umol/L, LDL 
3.1 mmol/L, alkaline phosphatase 114 U/L, ALT 18 U/L/, AST 
30 U/L, creatinine 107 umol/L, urea 350 µmol/L, total protein 
65 g/L, albumin 39 g/L, sodium 140 mmol/L, potassium 
5.0 mmol/L. Differential diagnoses of HIV, hepatitis B and 
C virus, thrombophilia, thyroid disorders were excluded by 
labo ratory tests. NT-proBNP was 845 pg/ml (RR <130 pg/ml). 
Index-anticentromer antibody IgG > 8.
Based on ACR (including the LeRoy and Medsger 
modifications) and the EULAR Criteria for Systemic Scle-
rosis [30], limited SSc was diagnosed as the presence of 
Raynaud’s syndrome plus SSc-specific autoantibodies.
Screening for PH using step 1 of the DETECT al-
gorhithm showed 329 risk score.
Further testing included TTE which showed a markedly 
dilated RV (end-diastolic diameter 51 mm) and right atrium 
(right atrium area 31 cm2), reduced tricuspid annular plane 
systolic excursion (TAPSE) (10 mm), severe tricuspid 
regurgitation (>2.6 mm/sec), RV/LV was 1.0, at the same 
time estimated systolic pulmonary artery pressure (sPAP) 
was 107 mmHg, abnormal function of the interventricular 
septum (IVS), a nonhaemodynamic relevant pericardial 
effusion (100 ml), and a dilated vena cava inferior (9.7 mm) 
were revealed. Left ventricle (LV) ejection fraction was 74 %, 
iLV mass – 64 g/cm2. There were no signs of congenital 
heart disease.
After calculating the total risk score by step 2 of the DE-
TECT algorithm, RHC was performed.
Hemodynamic evaluation by RHC verified pre-capillary 
PH: mPAP 48 mmHg, PAWP 9 mmHg and PVR of 800 
dyn*sec/cm5, cardiac index 2.0 l/min/m2. Mixed venous 
partial pressure of oxygen was 31 mmHg, arterial partial 
pressure of oxygen was 51 mmHg. Ventavis inhalation 
performed during RHC did not meet the criteria for an acute 
vasoreactive response.
Coronaroangiography findings included 65 % stenosis 
of left anterior descending artery and 30 % stenosis of left 
circumflex artery.
Abdomen ultrasound showed echo-signs of fatty liver 
disease. Portal vein was 1.0 cm. The wall of gallbladder 
was thickened up to 0.4 cm and hyperechoic, echogenicity 
of pancreas was increased without masses. Marked aortic 
sclerosis was seen.
As a result, the patient’s diagnosis was confirmed as 
mild PAH WHO FC II, associated with limited SSc, inter-
mediate risk. III stage of right heart failure with RV systolic 
dysfunction and LV preserved systolic function.
PAH treatment was initiated with Revatio 60 mg daily. 
Concomitant therapy consisted of Valsartan / Hydrochlo-
rothiazide 160/12.5 mg daily, Acetylsalicylic acid 75 mg 
daily, Atorvastatin 20 mg daily, Thorasemide 10 mg daily, 
Furosemide 40 mg daily, Spironolactone 50 mg daily. The 
patient had rheumatologist consultation, but no medications 
for SSc were administered.
The patient had remained clinically stable for 4 months. 
In March 2017, she was admitted to the hospital with 
tachycardia, worsening of right heart failure, signs of fluid 
retention and increased dyspnea, deterioration to NYHA III. 
There was atrial fibrillation on ECG with HR of 110 beats 
per minute and BP of 134/85 mmHg. Anticoagulation with 
Rivaroxaban 20 mg daily was initiated immediately. Due to 
aggravation of heart failure symptoms, early cardioversion 
was considered.
On transesophageal examination, right ventricle outflow 
tract thrombus and left atrial appendage thrombus were 
found. These results pointed on management the patient 
with rate control therapy. After escalation of diuretic therapy 
and achievement of rate control between 90–100 beats per 
minute, some improvement of right heart failure congestion 
symptoms was observed, but the patient still remained in 
NYHA III. In 6-MWT the covered distance was 170 m. TTE 
hemodynamic parameters did not differ from baseline: RV/
LV 1.0; sPAP 105 mmHg, iS RA 19.4 cm/m2, LVEF 65 %, 
paradoxical motion became more pronounced.
After clinical examination, we observed progression to 
NYHA FC III in our patient, but there were no TTE changes 
and no 6-MWD test decrease to 15 %. Right heart cathete-
rization was not done due to presence of RVOT thrombus. 
Decision about sequential drug combination therapy was 
done and Ventavis was administered additionally.
The patient had remained in the same clinical status 
without improvement following initiation of combination 
therapy. In October 2017, she suddenly died.
Our clinical case demonstrates outcomes of delayed 
SSc and PH diagnostics. Thus, limited SSc was established 
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in the 61-year-woman after 20 years of Raynaud’s syndrome 
anamnesis. During hospitalization with paralytic form of 
Raynaud’s syndrome in 2015, our patient had already 
complained of dyspnea, but none of these symptoms were 
taken in a point for SSc suspicion and subsequent screening 
for PH with the DETECT algorithm. Diagnosis of PAH was 
determined in severe and late symptomatic stage with signs 
of right heart congestion, NYHA III FC and mPAP 48 mmHg. 
This emphasizes the need for clinicians to be aware of 
limited SSc and have a high index of PH suspicion in such 
patients. Ongoing follow-up and critical re-evaluation of 
the diagnosis with individual assessment of clinical status, 
co-morbidities and treatment efficacy are essential due to 
the high risk of cardiovascular complications.
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